https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38113 Wed 04 Aug 2021 11:40:28 AEST ]]> Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> Comparative effectiveness in multiple sclerosis: A methodological comparison https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51450 Tue 05 Sep 2023 17:56:18 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Prediction of multiple sclerosis outcomes when switching to ocrelizumab https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>